Tryptamine Therapeutics Ltd

0.032

-0.002-5.88%

Volume:835.05K

Turnover:26.80K

Market Cap:46.05M

PE:-2.20

High:0.033

Open:0.032

Low:0.032

Close:0.034

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Tryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%

MT Newswires Live

·

29 Nov 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TYP.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","market":"AU","secType":"STK","nameCN":"Tryptamine Therapeutics Ltd","latestPrice":0.032,"timestamp":1744870320000,"preClose":0.034,"halted":0,"volume":835050,"delay":0,"nameEN":"Tryptamine Therapeutics Ltd","floatShares":886430573,"shares":1438921906,"eps":-0.014547,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"04-17 16:12:00 AEST","open":0.032,"high":0.033,"low":0.032,"amount":26803,"amplitude":0.029412,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.014547,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.034,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.3030538816585892,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","floatShares":886430573,"roa":"-367.10%","roe":"--","lyrEps":-0.012122,"volumeRatio":0.3030538816585892,"shares":1438921906,"dividePrice":0,"high":0.033,"amplitude":0.029412,"preClose":0.034,"low":0.032,"week52Low":0.017,"pbRate":"8.19","psRate":"34.69","week52High":0.057,"institutionHeld":0,"latestPrice":0.032,"eps":-0.014547,"divideRate":0,"volume":835050,"delay":0,"ttmEps":-0.014547,"open":0.032,"prevYearClose":0.038,"prevWeekClose":0.032,"prevMonthClose":0.036,"prevQuarterClose":0.036,"fiveDayClose":0.029,"twentyDayClose":0.036,"sixtyDayClose":0.038},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TYP.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TYP.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522310103","title":"Tryptamine Therapeutics Ltd-Proposed Issue of Securities - Typ","url":"https://stock-news.laohu8.com/highlight/detail?id=2522310103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522310103?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:25","pubTimestamp":1743060323,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUE5PJD7Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2501313479","title":"Tryptamine Therapeutics Appoints New Auditor; Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501313479","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501313479?lang=en_us&edition=fundamental","pubTime":"2025-01-06 12:10","pubTimestamp":1736136655,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  appointed BDO Audi as auditor, effective immediately, according to a Monday filing with the Australian bourse.The appointment follows the resignation of the company's former auditor William Buck Audit and the board's decision to choose an auditor registered with the Canadian Accounting Board, the filing said.Shares of the company fell past 7% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TYP.AU","LENZ","BK7096","BK4139"],"gpt_icon":0},{"id":"2491534501","title":"Tryptamine Therapeutics Ltd-Phase 1B Extension Results Meet Study Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2491534501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491534501?lang=en_us&edition=fundamental","pubTime":"2024-12-16 06:17","pubTimestamp":1734301076,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241215:nTUE3L616K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2487230111","title":"Tryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487230111","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487230111?lang=en_us&edition=fundamental","pubTime":"2024-11-29 12:54","pubTimestamp":1732856080,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.Company shares rose nearly 5% in recent Friday trade.Price : $0.05, Change: $+0.002, Percent Change: +4.65%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2238339852.HKD","LU0345774631.USD","AUD","LU1043141123.HKD","TYP.AU","BK7096","LENZ","LU0426412945.USD","BK4125","LU0426417589.USD","LU0994945656.USD","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TYP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TYP.AU\",market:\"AU\",,,undefined,":[]}}